Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
YB-1, the E2F pathway, and regulation of tumor cell growth.
Lasham A, Samuel W, Cao H, Patel R, Mehta R, Stern JL, Reid G, Woolley AG, Miller LD, Black MA, Shelling AN, Print CG, Braithwaite AW. Lasham A, et al. Among authors: print cg. J Natl Cancer Inst. 2012 Jan 18;104(2):133-46. doi: 10.1093/jnci/djr512. Epub 2011 Dec 28. J Natl Cancer Inst. 2012. PMID: 22205655 Free PMC article.
Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness.
Miller LD, Chou JA, Black MA, Print C, Chifman J, Alistar A, Putti T, Zhou X, Bedognetti D, Hendrickx W, Pullikuth A, Rennhack J, Andrechek ER, Demaria S, Wang E, Marincola FM. Miller LD, et al. Cancer Immunol Res. 2016 Jul;4(7):600-10. doi: 10.1158/2326-6066.CIR-15-0149. Epub 2016 Apr 28. Cancer Immunol Res. 2016. PMID: 27197066 Free PMC article.
Tumor mutational burden is a determinant of immune-mediated survival in breast cancer.
Thomas A, Routh ED, Pullikuth A, Jin G, Su J, Chou JW, Hoadley KA, Print C, Knowlton N, Black MA, Demaria S, Wang E, Bedognetti D, Jones WD, Mehta GA, Gatza ML, Perou CM, Page DB, Triozzi P, Miller LD. Thomas A, et al. Oncoimmunology. 2018 Jul 30;7(10):e1490854. doi: 10.1080/2162402X.2018.1490854. eCollection 2018. Oncoimmunology. 2018. PMID: 30386679 Free PMC article.
Bulk and Single-Cell Profiling of Breast Tumors Identifies TREM-1 as a Dominant Immune Suppressive Marker Associated With Poor Outcomes.
Pullikuth AK, Routh ED, Zimmerman KD, Chifman J, Chou JW, Soike MH, Jin G, Su J, Song Q, Black MA, Print C, Bedognetti D, Howard-McNatt M, O'Neill SS, Thomas A, Langefeld CD, Sigalov AB, Lu Y, Miller LD. Pullikuth AK, et al. Front Oncol. 2021 Dec 8;11:734959. doi: 10.3389/fonc.2021.734959. eCollection 2021. Front Oncol. 2021. PMID: 34956864 Free PMC article.
Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures.
Hossain SM, Gimenez G, Stockwell PA, Tsai P, Print CG, Rys J, Cybulska-Stopa B, Ratajska M, Harazin-Lechowska A, Almomani S, Jackson C, Chatterjee A, Eccles MR. Hossain SM, et al. Among authors: print cg. Front Immunol. 2022 Sep 28;13:955063. doi: 10.3389/fimmu.2022.955063. eCollection 2022. Front Immunol. 2022. PMID: 36248850 Free PMC article.
Cell cycle gene networks are associated with melanoma prognosis.
Wang L, Hurley DG, Watkins W, Araki H, Tamada Y, Muthukaruppan A, Ranjard L, Derkac E, Imoto S, Miyano S, Crampin EJ, Print CG. Wang L, et al. Among authors: print cg. PLoS One. 2012;7(4):e34247. doi: 10.1371/journal.pone.0034247. Epub 2012 Apr 20. PLoS One. 2012. PMID: 22536322 Free PMC article.
Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells.
Caldon CE, Sergio CM, Kang J, Muthukaruppan A, Boersma MN, Stone A, Barraclough J, Lee CS, Black MA, Miller LD, Gee JM, Nicholson RI, Sutherland RL, Print CG, Musgrove EA. Caldon CE, et al. Among authors: print cg. Mol Cancer Ther. 2012 Jul;11(7):1488-99. doi: 10.1158/1535-7163.MCT-11-0963. Epub 2012 May 7. Mol Cancer Ther. 2012. PMID: 22564725
140 results